Jason Gerberry
Stock Analyst at B of A Securities
(3.42)
# 892
Out of 4,842 analysts
160
Total ratings
52.63%
Success rate
1.34%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $17.71 | +24.22% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $31.73 | +331.77% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $14.29 | +130.93% | 5 | Mar 20, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $8.60 | +16.28% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $103.98 | +60.61% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $24.84 | +20.77% | 2 | Jan 9, 2025 | |
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $43.09 | -9.49% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $5.00 | +100.00% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $61.95 | +61.42% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $15.34 | +304.17% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $2.85 | +742.11% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.73 | +310.96% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $33.32 | +104.08% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $19.89 | +0.55% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.97 | +7.01% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.09 | +12,428.47% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $29.90 | -2.99% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $15.37 | +140.73% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $29.46 | +90.09% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $33.76 | -11.14% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $25.54 | +146.67% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $109.46 | +98.25% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.32 | +522.08% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $725.22 | -31.06% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.08 | +733.33% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $9.14 | +173.52% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.70 | +193.39% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $4.59 | +488.24% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.78 | +2,466.41% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.57 | +1,645.51% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $185.72 | -48.85% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $46.89 | +27.96% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $23.61 | +56.71% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $77.59 | +15.99% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $17.71
Upside: +24.22%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $31.73
Upside: +331.77%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $14.29
Upside: +130.93%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $8.60
Upside: +16.28%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $103.98
Upside: +60.61%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $24.84
Upside: +20.77%
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $43.09
Upside: -9.49%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $5.00
Upside: +100.00%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $61.95
Upside: +61.42%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $15.34
Upside: +304.17%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $2.85
Upside: +742.11%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.73
Upside: +310.96%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $33.32
Upside: +104.08%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $19.89
Upside: +0.55%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.97
Upside: +7.01%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.09
Upside: +12,428.47%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $29.90
Upside: -2.99%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $15.37
Upside: +140.73%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $29.46
Upside: +90.09%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $33.76
Upside: -11.14%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $25.54
Upside: +146.67%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $109.46
Upside: +98.25%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.32
Upside: +522.08%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $725.22
Upside: -31.06%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.08
Upside: +733.33%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $9.14
Upside: +173.52%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.70
Upside: +193.39%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $4.59
Upside: +488.24%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.78
Upside: +2,466.41%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.57
Upside: +1,645.51%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $185.72
Upside: -48.85%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $46.89
Upside: +27.96%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $23.61
Upside: +56.71%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $77.59
Upside: +15.99%